RNC Capital Management LLC Reduces Stock Holdings in Merck & Co., Inc. $MRK

RNC Capital Management LLC trimmed its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 5.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 371,524 shares of the company's stock after selling 22,163 shares during the period. RNC Capital Management LLC's holdings in Merck & Co., Inc. were worth $29,410,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Legend Financial Advisors Inc. purchased a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at about $25,000. Barnes Dennig Private Wealth Management LLC purchased a new position in shares of Merck & Co., Inc. during the 1st quarter valued at about $27,000. CBIZ Investment Advisory Services LLC lifted its position in shares of Merck & Co., Inc. by 141.7% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company's stock valued at $34,000 after buying an additional 221 shares in the last quarter. MorganRosel Wealth Management LLC purchased a new position in shares of Merck & Co., Inc. during the 1st quarter valued at about $36,000. Finally, Advantage Trust Co lifted its position in shares of Merck & Co., Inc. by 57.1% during the 2nd quarter. Advantage Trust Co now owns 550 shares of the company's stock valued at $44,000 after buying an additional 200 shares in the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on MRK. Weiss Ratings reissued a "hold (c-)" rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Morgan Stanley decreased their target price on Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. Citigroup began coverage on Merck & Co., Inc. in a research note on Monday, October 13th. They set a "neutral" rating and a $95.00 target price on the stock. Wells Fargo & Company decreased their target price on Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 30th. Finally, Berenberg Bank downgraded Merck & Co., Inc. from a "buy" rating to a "hold" rating and decreased their target price for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $104.33.

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock opened at $87.60 on Thursday. The stock has a market cap of $218.81 billion, a price-to-earnings ratio of 13.50, a price-to-earnings-growth ratio of 0.96 and a beta of 0.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The stock has a 50 day moving average price of $84.28 and a 200-day moving average price of $81.43. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $107.36.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, topping analysts' consensus estimates of $2.03 by $0.10. The firm had revenue of $15.81 billion during the quarter, compared to analysts' expectations of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Equities analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.